HSTO Stock Overview
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.33|
|52 Week High||US$22.20|
|52 Week Low||US$2.06|
|1 Month Change||-33.96%|
|3 Month Change||-53.40%|
|1 Year Change||-89.31%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-97.47%|
Recent News & Updates
|HSTO||US Biotechs||US Market|
Return vs Industry: HSTO underperformed the US Biotechs industry which returned -26.1% over the past year.
Return vs Market: HSTO underperformed the US Market which returned -20.4% over the past year.
|HSTO Average Weekly Movement||25.7%|
|Biotechs Industry Average Movement||13.1%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: HSTO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.
Volatility Over Time: HSTO's weekly volatility has increased from 14% to 26% over the past year.
About the Company
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company’s preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease.
Histogen Fundamentals Summary
|HSTO fundamental statistics|
Is HSTO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HSTO income statement (TTM)|
|Cost of Revenue||US$8.25m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.55|
|Net Profit Margin||-260.63%|
How did HSTO perform over the long term?See historical performance and comparison
Is HSTO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HSTO?
Other financial metrics that can be useful for relative valuation.
|What is HSTO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does HSTO's PS Ratio compare to its peers?
|HSTO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ANPC AnPac Bio-Medical Science
CELZ Creative Medical Technology Holdings
Price-To-Sales vs Peers: HSTO is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (24.5x).
Price to Earnings Ratio vs Industry
How does HSTO's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: HSTO is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Biotechs industry average (13.4x)
Price to Sales Ratio vs Fair Ratio
What is HSTO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.3x|
|Fair PS Ratio||1.9x|
Price-To-Sales vs Fair Ratio: HSTO is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).
Share Price vs Fair Value
What is the Fair Price of HSTO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HSTO ($2.33) is trading below our estimate of fair value ($750.68)
Significantly Below Fair Value: HSTO is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HSTO's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Histogen forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if HSTO's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if HSTO's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if HSTO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HSTO's revenue (54% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: HSTO's revenue (54% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HSTO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Histogen performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HSTO is currently unprofitable.
Growing Profit Margin: HSTO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HSTO is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.
Accelerating Growth: Unable to compare HSTO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HSTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: HSTO has a negative Return on Equity (-47.65%), as it is currently unprofitable.
Discover strong past performing companies
How is Histogen's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: HSTO's short term assets ($25.8M) exceed its short term liabilities ($2.9M).
Long Term Liabilities: HSTO's short term assets ($25.8M) exceed its long term liabilities ($4.7M).
Debt to Equity History and Analysis
Debt Level: HSTO is debt free.
Reducing Debt: HSTO had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HSTO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HSTO has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 48.5% each year.
Discover healthy companies
What is Histogen current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HSTO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HSTO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HSTO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HSTO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HSTO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Mento (69 yo)
Dr. Steven J. Mento, also known as Steve, Ph D., has been an Executive Chairman, Interim President and Chief Executive Officer of Histogen Inc. since November 08, 2021. Dr. Mento has been an Independent Di...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD686.21K) is about average for companies of similar size in the US market ($USD759.63K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Management: HSTO's management team is seasoned and experienced (5.1 years average tenure).
Experienced Board: HSTO's board of directors are considered experienced (8.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.
Histogen Inc.'s employee growth, exchange listings and data sources
- Name: Histogen Inc.
- Ticker: HSTO
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.819m
- Shares outstanding: 2.50m
- Website: https://www.histogen.com
Number of Employees
- Histogen Inc.
- 10655 Sorrento Valley Road
- Suite 200
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.